CRVS News and Press, Corvus Pharmaceuticals Inc. From 04/17/23

Preclinical data supports targeting ITK as a new approach for cancer immunotherapy Novel mechanism of action modulates T cell differentiation and enhances the immune system via Th1 skewing, increased T cell cytolytic capacity and reduction of T cell exhaustion Enrollment continu...

2023-04-12 12:55:56 ET Gainers: National CineMedia ( NCMI ) +151% . TESSCO Technologies Incorporated ( TESS ) +87% . Guardforce AI ( GFAI ) +51% . Bullfrog AI Holdings ( BFRG ) +32% . Altamira Therapeutics ( CYTO ) +28% . Tri...

Interim data from Phase 1/1b clinical trial of CPI-818, including new evidence supporting the recently implemented minimum absolute lymphocyte count (ALC) predictive biomarker Data presented at the 10 th Whistler Global Summit on Hematologic Malignancies BURLINGAME, Ca...

2023-03-28 22:55:16 ET Corvus Pharmaceuticals, Inc. (CRVS) Q4 2022 Earnings Conference Call March 27, 2023, 04:30 PM ET Company Participants Zack Kubow - Investor Relations-Real Chemistry Leiv Lea - Chief Financial Officer Richard Miller - Co-Founder, President &...

2023-03-28 16:06:40 ET Corvus Pharmaceuticals press release ( NASDAQ: CRVS ): Q4 GAAP EPS of -$0.21 beats by $0.02 . As of December 31, 2022, Corvus had cash, cash equivalents and marketable securities totaling $42.3 million. This compared to cash, cash equivalent...

New CPI-818 Predictive Biomarker Enables Selection of Lymphoma Patients Most Likely to Benefit from Treatment Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: C...

2023-03-27 17:35:09 ET Major earnings expected after the bell on Tuesday include: Micron Technology ( MU ) Lululemon Athletica ( LULU ) Ideanomics ( IDEX ) Emeren Group ( SOL ) nCino ( NCNO ) For further details see: Notable earnings after...

BURLINGAME, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on March 28, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update and re...

BURLINGAME, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new data for CPI-818, the Company’s ITK inhibitor, at the American Association for Cancer Research (AACR) Ann...

Findings may provide a treatment that enables discontinuation of HIV antiretroviral therapy by preventing re-emergence of the virus Data to be presented at the Conference on Retroviruses and Opportunistic Infections Research partners from UCSF and Vitalant to continue studying p...